HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Abstract
The high-grade pulmonary neuroendocrine tumors, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), remain among the most deadly malignancies. Therapies that effectively target and kill tumor-initiating cells (TICs) in these cancers should translate to improved patient survival. Patient-derived xenograft (PDX) tumors serve as excellent models to study tumor biology and characterize TICs. Increased expression of delta-like 3 (DLL3) was discovered in SCLC and LCNEC PDX tumors and confirmed in primary SCLC and LCNEC tumors. DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues. A DLL3-targeted antibody-drug conjugate (ADC), SC16LD6.5, comprised of a humanized anti-DLL3 monoclonal antibody conjugated to a DNA-damaging pyrrolobenzodiazepine (PBD) dimer toxin, induced durable tumor regression in vivo across multiple PDX models. Serial transplantation experiments executed with limiting dilutions of cells provided functional evidence confirming that the lack of tumor recurrence after SC16LD6.5 exposure resulted from effective targeting of DLL3-expressing TICs. In vivo efficacy correlated with DLL3 expression, and responses were observed in PDX models initiated from patients with both limited and extensive-stage disease and were independent of their sensitivity to standard-of-care chemotherapy regimens. SC16LD6.5 effectively targets and eradicates DLL3-expressing TICs in SCLC and LCNEC PDX tumors and is a promising first-in-class ADC for the treatment of high-grade pulmonary neuroendocrine tumors.
AuthorsLaura R Saunders, Alexander J Bankovich, Wade C Anderson, Monette A Aujay, Sheila Bheddah, KristenAnn Black, Radhika Desai, Paul A Escarpe, Johannes Hampl, Amy Laysang, David Liu, Javier Lopez-Molina, Milly Milton, Albert Park, Marybeth A Pysz, Hui Shao, Brian Slingerland, Michael Torgov, Samuel A Williams, Orit Foord, Philip Howard, Jacek Jassem, Andrzej Badzio, Piotr Czapiewski, David H Harpole, Afshin Dowlati, Pierre P Massion, William D Travis, M Catherine Pietanza, J T Poirier, Charles M Rudin, Robert A Stull, Scott J Dylla
JournalScience translational medicine (Sci Transl Med) Vol. 7 Issue 302 Pg. 302ra136 (Aug 26 2015) ISSN: 1946-6242 [Electronic] United States
PMID26311731 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015, American Association for the Advancement of Science.
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • DLL3 protein, human
  • Immunoconjugates
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
Topics
  • Animals
  • Antibodies, Monoclonal (immunology)
  • Antineoplastic Agents (therapeutic use)
  • Female
  • Humans
  • Immunoconjugates (therapeutic use)
  • Intracellular Signaling Peptides and Proteins (immunology, metabolism)
  • Lung Neoplasms (drug therapy, metabolism)
  • Membrane Proteins (immunology, metabolism)
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Neuroendocrine Tumors (drug therapy, metabolism)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: